HST-NEETs

HST-NEETs are ex vivo expanded, HIV-specific T cell therapies designed to target conserved, non-escaped epitopes of the HIV virus. These products are manufactured from either autologous or donor-derived peripheral blood mononuclear cells and are enriched for CD8+ and CD4+ T cells that recognize multiple conserved regions within the Gag, Pol, and Nef proteins of HIV. The rationale is to overcome viral escape by focusing on epitopes that remain unmutated in most circulating viruses. Upon infusion into individuals living with well-controlled HIV on antiretroviral therapy (ART), these T cells expand in vivo and persist for extended periods. Clinical studies have demonstrated safety and tolerability without serious product-related toxicities; some participants showed expansion of product-associated clones and a trend toward reduction in the size of the intact proviral reservoir post-infusion. The therapy is being investigated both as a stand-alone intervention in ART-suppressed individuals and as an adjunct following autologous stem cell transplantation for people with HIV-associated lymphoma[5][6][9][10].

Other names

HIV-specific T cells with non-escaped epitope targetingDonor Derived HIV-Specific T-cells with Non-escaped Epitope Targets